Organogenesis Inc., a commercial leader in the field of regenerative medicine, presented new data generated in collaboration with a team of expert economists from Analysis Group (a leading health economics consultancy) demonstrating the significant healthcare resource and economic burden that diabetic foot ulcers and venous leg ulcers place upon the US healthcare system.
[More]
Upsher-Smith Laboratories, Inc. today announced the successful completion of its global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.
[More]
Like most over-the-counter products, not all sunscreens are created equal. Some sunscreens provide higher sun protection, while others contain ingredients that are better suited for children's skin. The key is choosing a sunscreen that will provide the best sun protection for all family members, and combining sunscreen use with other sun-smart behaviors.
[More]
A medication’s optimal results are achieved with specific dose levels and times of administration. In order for patients to achieve the maximum benefit from a medication, they have to adhere to the prescribed dose and time of use.
[More]
Men often suffer from more severe cases of psoriasis than women, which may explain why the cost of care for men is higher. This is the conclusion of researchers at Umeå University in a new study.
[More]
Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients.
[More]
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID 2% product.
[More]
More than 100,000 Geisinger Health System patients will have access to their doctors' notes for the first time through the secure MyGeisinger online patient portal when Geisinger expands OpenNotes in May due to the initiative's overwhelming success.
[More]
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
[More]
Today, the U.S. Food and Drug Administration issued a proposed order that, if finalized, would reclassify sunlamp products and require labeling to include a recommendation designed to warn young people not to use these devices.
[More]
The American Academy of Dermatology Association (AADA) is pleased that the U.S. Food and Drug Administration (FDA) has proposed changes to its regulation of tanning beds, including a strong recommendation against the use of tanning beds by minors under the age of 18.
[More]
Nuvo Research Inc. (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation"), as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012, on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share.
[More]
Having one blistering sunburn in childhood or adolescence more than doubles a person's chance of developing melanoma later in life, yet less than one-third of all young people take the proper steps to protect their skin from excessive sun exposure, according to the Skin Cancer Foundation.
[More]
Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).
[More]
Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.
[More]
Unethical behavior among physicians-in-training threatens to erode public trust and confidence in the medical profession, say two academic physicians in the current issue of Mayo Clinic Proceedings.
[More]
The American Academy of Dermatology aims to paint the nation orange this May by asking the public to wear orange in support of skin cancer awareness on Melanoma Monday, May 6.
[More]
Golfers may have more to worry about than just their short game or backswing this summer. They also may be at risk for skin cancer, according to dermatologists at Loyola University Health System.
[More]
Surgery is often recommended for skin cancers, but older, sicker patients can endure complications as a result and may not live long enough to benefit from the treatment.
[More]
Use of biventricular rather than conventional right ventricular pacing results in better clinical outcomes in patients who have heart failure with atrioventricular block and left ventricular systolic dysfunction, show the results of BLOCK HF.
[More]